Pay in 4 interest-free payments of $6.89 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
Funding The author(s) declare financial support was received for the research, authorship, and/or publication of this article
Image available at: Image with caption: "Perceptions of the transition to and use of injectable medications in type 2 diabetes (CNW Group/Eli Lilly Canada Inc.)"
Moving forward, the results of the phase 3 SURPASS clinical trial program demonstrated that tirzepatide was as effective and safe as other anti-diabetic agents, such as semaglutide and dulaglutide (SURPASS-2) (SURPASS J-mono), long-acting insulin analogs (degludec and glargine) (SURPASS-3,4), and placebo (SURPASS-1) (SURPASS-5), in managing T2DM diabetes [65,66,67,68,69]
Your gut cells release GLP-1 after every meal, every day, as part of the ordinary process of coordinating digestion, blood sugar, and satiety
They prompt the pancreas to release more insulin when blood sugar rises and they blunt glucagon, the hormone that raises blood sugar a dual action that helps keep glucose steady
Othman, A
US$ 24.71
US$ 26.12
US$ 28.04
US$ 22.21
US$ 20.52
